FilingReader Intelligence
Jolly Pharmaceutical forecasts strong growth, forges research partnership
July 9, 2025 at 08:49 AM UTC•By FilingReader AI
Zhejiang Jolly Pharmaceutical projects a significant rise in net profit attributable to shareholders for the first half of 2025, estimating a range of CNY 368 million to CNY 388 million, representing a 24.30% to 31.06% increase year-over-year. Excluding the impact of share-based payment expenses, the projected net profit would range from CNY 381.74 million to CNY 401.74 million, a 28.94% to 35.70% increase.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:300181•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Jolly Pharmaceutical publishes news
Free account required • Unsubscribe anytime